What is the appropriate dose of doxapram and how should it be administered?

Doxapram Dosing and Administration

For postanesthetic respiratory depression, administer doxapram as an IV bolus of 0.5-1 mg/kg every 5 minutes (maximum 2 mg/kg total) or as a continuous infusion starting at 5 mg/min until respiratory response occurs, then maintain at 1-3 mg/min (maximum 4 mg/kg or ~300 mg total). 1

Route of Administration

Doxapram should be administered intravenously in clinical practice. The FDA-approved formulation is for IV use only 1.

• IV bolus: Most direct method for acute situations
• Continuous IV infusion: Preferred for sustained respiratory stimulation with better control of effects

Oral doxapram is not recommended despite research exploring this route. Studies show poor gastrointestinal absorption in neonates (bioavailability suggesting only 10-12% absorption) and significant interpatient variability 2. While recent trials in preterm infants showed feasibility, most achieved supra-therapeutic levels even at lower doses, indicating unpredictable absorption 3.

Specific Clinical Scenarios

Postanesthetic Use (FDA-Approved)

IV Bolus Method:

• Initial dose: 0.5-1 mg/kg as single injection
• Repeat at 5-minute intervals if needed
• Maximum total: 2 mg/kg 1

Continuous Infusion Method:

• Preparation: Add 250 mg doxapram (12.5 mL) to 250 mL of D5W, D10W, or normal saline
• Initial rate: ~5 mg/min until satisfactory response
• Maintenance: 1-3 mg/min, titrated to effect
• Maximum total: 4 mg/kg or approximately 300 mg 1

Drug-Induced CNS Depression

Method One - Intermittent Boluses:

• Mild depression (Class 0-1): Priming dose 1 mg/kg
• Moderate depression (Class 2-3): Priming dose 2 mg/kg
• Repeat in 5 minutes, then every 1-2 hours as needed
• Maximum: 3 grams per 24 hours 1

Method Two - Intermittent Infusion:

• Give priming dose as above
• If partial response: Prepare infusion (250 mg in 250 mL saline/dextrose)
• Deliver at 1-3 mg/min (60-180 mL/hr) based on patient size and coma depth
• Discontinue after 2 hours or if patient wakens
• Maximum: 3 grams/day 1

COPD with Acute Hypercapnia

• Preparation: 400 mg doxapram in 180 mL D5W, D10W, or normal saline (concentration 2 mg/mL)
• Initial rate: 1-2 mg/min (0.5-1 mL/min)
• Maximum: 3 mg/min
• Critical: Monitor arterial blood gases before starting and every 30 minutes during infusion
• Maximum duration: 2 hours; additional infusions beyond this are NOT recommended 1

Apnea of Prematurity (Off-Label)

When methylxanthines fail, doxapram can be considered, though evidence is limited:

• Starting dose: 0.5 mg/kg/hr continuous IV infusion 4
• Titrate upward in 0.5 mg/kg/hr increments based on response
• Most infants respond by 2.0 mg/kg/hr (82% response rate)
• Maximum studied: 2.5 mg/kg/hr (89% response rate)
• Target serum level: >1.5 mcg/mL (mean effective level 2.9 ± 1.3 mcg/mL) 4

Important caveat: The Cochrane review found very uncertain evidence for doxapram's efficacy in apnea of prematurity, with potential for side effects 5. Use only when methylxanthines have definitively failed.

Preparation and Compatibility

Compatible diluents:

• 5% or 10% dextrose in water
• Normal saline 1

INCOMPATIBLE - will precipitate or form gas:

• Alkaline solutions (sodium bicarbonate, thiopental)
• Furosemide
• Aminophylline
• Multiple other medications including cephalosporins, steroids, diazepam 1

Always prepare fresh solutions and avoid mixing with other medications.

Critical Monitoring Requirements

• Blood pressure and heart rate: Continuously during infusion (doxapram causes dose-dependent BP elevation, especially >1.5 mg/kg/hr) 4
• Deep tendon reflexes: To detect CNS overstimulation 1
• Arterial blood gases: Every 30 minutes in COPD patients to prevent CO2 retention 1
• Respiratory rate and pattern: Continuous observation
• IV site: Avoid extravasation (causes thrombophlebitis); rotate sites 1

Major Contraindications and Warnings

Absolute contraindications:

• Severe hypertension
• Seizure disorders
• Airway obstruction
• Increased intracranial pressure 1

Common pitfalls:

• Rapid infusion causes hemolysis - always infuse slowly 1
• Vomiting risk - ensure adequate airway protection 1
• Additive pressor effects with sympathomimetics or MAO inhibitors 1
• Contains benzyl alcohol - consider in neonates (gasping syndrome risk) 1

Have ready at bedside:

• Short-acting IV barbiturates for seizures
• Oxygen and resuscitation equipment
• Anticonvulsants 1

The terminal elimination half-life is approximately 10 hours 4, so effects may persist well beyond infusion cessation - continue monitoring for respiratory depression rebound.